A detailed history of Geode Capital Management, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,565,145 shares of CHRS stock, worth $3.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,565,145
Previous 2,382,231 7.68%
Holding current value
$3.9 Million
Previous $4.12 Million 35.28%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.99 - $1.8 $181,084 - $329,245
182,914 Added 7.68%
2,565,145 $2.67 Million
Q2 2024

Aug 09, 2024

BUY
$1.58 - $2.51 $282,088 - $448,127
178,537 Added 8.1%
2,382,231 $4.12 Million
Q1 2024

May 13, 2024

BUY
$2.02 - $3.14 $246,627 - $383,372
122,093 Added 5.87%
2,203,694 $5.27 Million
Q4 2023

Feb 13, 2024

BUY
$1.59 - $3.85 $217,248 - $526,040
136,634 Added 7.03%
2,081,601 $6.93 Million
Q3 2023

Nov 13, 2023

BUY
$3.74 - $5.45 $1.96 Million - $2.86 Million
524,359 Added 36.91%
1,944,967 $7.27 Million
Q2 2023

Aug 11, 2023

BUY
$3.79 - $8.3 $425,382 - $931,575
112,238 Added 8.58%
1,420,608 $6.07 Million
Q1 2023

May 15, 2023

BUY
$5.89 - $10.52 $282,425 - $504,434
47,950 Added 3.8%
1,308,370 $8.95 Million
Q4 2022

Feb 13, 2023

BUY
$5.69 - $10.07 $177,590 - $314,294
31,211 Added 2.54%
1,260,420 $9.98 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $13.87 $231,999 - $448,791
32,357 Added 2.7%
1,229,209 $11.8 Million
Q2 2022

Aug 12, 2022

BUY
$5.86 - $13.23 $168,744 - $380,971
28,796 Added 2.47%
1,196,852 $8.67 Million
Q1 2022

May 13, 2022

SELL
$10.92 - $16.41 $291,607 - $438,212
-26,704 Reduced 2.24%
1,168,056 $15.1 Million
Q4 2021

Feb 11, 2022

SELL
$15.81 - $18.99 $47,809 - $57,425
-3,024 Reduced 0.25%
1,194,760 $19.1 Million
Q3 2021

Nov 12, 2021

BUY
$12.68 - $17.79 $180,258 - $252,902
14,216 Added 1.2%
1,197,784 $19.2 Million
Q2 2021

Aug 13, 2021

BUY
$12.95 - $15.41 $1.09 Million - $1.3 Million
84,257 Added 7.66%
1,183,568 $16.4 Million
Q1 2021

May 12, 2021

BUY
$14.42 - $21.39 $1.61 Million - $2.39 Million
111,841 Added 11.33%
1,099,311 $16.1 Million
Q4 2020

Feb 12, 2021

BUY
$16.56 - $18.94 $487,029 - $557,025
29,410 Added 3.07%
987,470 $17.2 Million
Q3 2020

Nov 13, 2020

BUY
$17.41 - $19.89 $53,988 - $61,678
3,101 Added 0.32%
958,060 $17.6 Million
Q2 2020

Aug 13, 2020

SELL
$14.43 - $19.16 $202,351 - $268,680
-14,023 Reduced 1.45%
954,959 $17.1 Million
Q1 2020

May 14, 2020

BUY
$11.67 - $22.53 $873,336 - $1.69 Million
74,836 Added 8.37%
968,982 $15.7 Million
Q4 2019

Feb 13, 2020

BUY
$16.33 - $21.37 $613,632 - $803,020
37,577 Added 4.39%
894,146 $16.1 Million
Q3 2019

Nov 12, 2019

BUY
$16.3 - $23.37 $1.07 Million - $1.53 Million
65,606 Added 8.29%
856,569 $17.4 Million
Q2 2019

Aug 14, 2019

BUY
$13.1 - $22.1 $1.23 Million - $2.08 Million
93,978 Added 13.48%
790,963 $17.5 Million
Q1 2019

May 14, 2019

BUY
$8.38 - $15.5 $557,353 - $1.03 Million
66,510 Added 10.55%
696,985 $9.51 Million
Q4 2018

Feb 13, 2019

SELL
$8.65 - $16.28 $46,182 - $86,918
-5,339 Reduced 0.84%
630,475 $5.71 Million
Q3 2018

Nov 13, 2018

BUY
$14.45 - $20.25 $1.86 Million - $2.6 Million
128,389 Added 25.3%
635,814 $10.5 Million
Q2 2018

Aug 14, 2018

BUY
$10.25 - $17.45 $728,744 - $1.24 Million
71,097 Added 16.29%
507,425 $7.1 Million
Q1 2018

May 15, 2018

BUY
$9.1 - $13.7 $430,566 - $648,215
47,315 Added 12.16%
436,328 $4.82 Million
Q4 2017

Feb 13, 2018

BUY
$8.35 - $14.4 $80,335 - $138,542
9,621 Added 2.54%
389,013 $3.42 Million
Q3 2017

Nov 14, 2017

BUY
$11.1 - $14.5 $624,552 - $815,857
56,266 Added 17.41%
379,392 $5.06 Million
Q2 2017

Aug 14, 2017

BUY
N/A
323,126
323,126 $4.64 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $118M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.